Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)
Northwest Biotherapeutics, Inc (OTCMKTS:NWBO), headquartered in Bethesda, MD, is a clinical stage biotechnology company that develops personalized cancer vaccines to treat a wide range of solid tumor cancers. The company has a market capitalization of over $35 million and trades less than 1.5 million shares daily based on their 30-day average. Today NWBO share volumes are trading at four times their averages.
At the center of their strategic advantage is the DCVax technology platform. DCVax uses activated dendritic cells (the master cells of the immune system) to educate the body’s entire immune system on how to attack a cancer. Conventional cancer treatments use one active agent to hit one target on the cancer while DCVax uses many active agents to hit many targets on the cancer. Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) believes there are three aspects of the DCVax system that have indicated promise for the technology. First, the DCVax system mobilizes the entire immune system, not just a single immune agent. Secondly, DCVax targets all of the biomarkers on a cancer patient’s tumor, not just one. Lastly, DCVax uses the patient’s own tumor to develop the specific treatment. This highly customized approach has, to date, produced positive results. DCVax has achieved clinical benefits. Over 80% of the patients who were treated with the DCVax system approach experienced a longer delay in the cancer’s progression and an extension of survival when compared to patients who received a more traditional standard of care.
Three drug candidates are in the Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) pipeline. DCVax-L is in Phase 3 trails for the indication of brain cancer and in Phase 2 trials for the indication of metastatic overian cancer. DCVax-Direct has a Phase 1/2 trial underway currently. DCVax-Prostate has been cleared by the FDA for Phase 3 trials and Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) is currently searching for an appropriate partner to begin the trial.
Over a month ago, Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) closed on a $7.5 million fund raise with several institutional investors. The common shares were priced at $0.26 per share while the class C warrants were priced at an exercise price of$0.25 with $0.01 to be paid per share when exercised. This was done in order to ensure all of the investor’s equity stayed below 5%.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading.